Abstract Library

#3735 Longitudinal changes in Ki-67 index in a prospective cohort of pancreatic neuroendocrine tumors

Introduction: The biology of pancreatic neuroendocrine tumors (panNET) can change over time. In retrospective cohorts, many panNETs showed longitudinal increases in Ki-67 index leading to a higher tumor grade and poor survival. However, data from prospective studies are lacking, and non-invasive methods of determining tumor grade progression are needed in order to monitor and guide further treatment.

Conference:

Presenting Author: Mollazadegan K

Authors: Mollazadegan K, Botling J, Welin S, Zhang L, Eriksson B,

Keywords: neuroendocrine tumor, pancreas, high-grade, poor prognosis, biomarker, Ki-67,

#2822 Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors

Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mollazadegan K, Botling J, Welin S, Eriksson B, Skogseid B,

Keywords: pancreas, neuroendocrine tumor, treatment,

#906 Secondary Hormonal Syndromes in Patients with Sporadic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are characterized by secretion of peptide hormones that may cause distinct syndromes. Although most patients with hormonal secretion are diagnosed upon primary diagnosis, a significant proportion of pancreatic NET patients develop secondary hormonal production later on in the disease.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Crona J, Eriksson B, Welin S,

Keywords: neuroendocrine tumor, prognostic factors,

#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1

Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Falkerby J, Granberg D, Eriksson B, Skogseid B, Öberg K,

Keywords: neuroendocrine, Everolimus, pancreatic,

#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP

Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlovacki G, Welin S, Eriksson B, Granberg D, Gaasvik-Blomqvist L,

Keywords: pasireotide, octreotide LAR, small intestinal NET, diarrhea, VIP ,